Board summary
Key figures
49,072
Registered population
58.6% aged 18–64
22.6%
Aged 65+
ICB 20.0% · England 17.9%
1.2%
Ethnic minority (non-White)
0.8% Asian · England 9.6%
17.0%
In IMD quintile 1
ICB 30.6% · England 21.0%
~7,717
Core20 residents (est.)
Resident basis; registered basis ~8,813 · see page 3
8,657
Hypertension register
+6.45% in 3 yrs · England +5.60%
484
SMI register
42.7% of South Ribble's
996
COPD register
Reviews -9.45% in 3 yrs
Forecast to 2030
10,176
Hypertension patients, 2030
+1,519 on today
62.1%
QRISK ≥20% on statins, 2030
+2.32pp over 3 yrs
5.8%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
High-risk lipid therapy and BP control lag.
Only 57.2% of patients with QRISK ≥20% receive lipid-lowering therapy (England 63.6%) and 65.9% with hypertension meet BP targets (England 70.3%).
Asthma annual reviews fell over three years.
Asthma review coverage is 64.0% (England 65.7%) after a -5.2% three-year change (England +4.4%), leaving about 1,200 register patients unreviewed.
Breast and cervical screening exceed national benchmarks.
Breast screening coverage is 76.2% (England 69.9%; +12.2% three-year change vs England +8.4%) and cervical screening aged 25-49 is 74.1% (England 66.8%).
Population, age and ethnicity
An older population of 22.6% aged 65+ may elevate local primary care demand
Leyland PCN encompasses 49,072 registered patients across six practices. The population is older than benchmarks: 22.6% (11,095 patients) are aged 65+, compared with 21.4% in South Ribble, 20.0% in NHS Lancashire and South Cumbria ICB, and 17.9% in England. Census usual-resident estimates in associated areas indicate a 98.8% White population (South Ribble 95.4%, ICB 87.8%, England 81.1%) and a 1.2% non-White ethnic minority share, including 0.8% Asian residents (South Ribble 2.1%, ICB 9.4%, England 9.6%). Projected list growth to 2030 is 2.1% (South Ribble 0.8%, ICB 1.7%, England 2.3%) using unverified projection methodology.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are South Ribble local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (South Ribble LA) | 1,600 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 75.5% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.3% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (South Ribble LA) | 826 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (South Ribble LA) | 9.2 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
A 17.0% Core20 share masks a 74.0 percentage point spread across member practices
Leyland PCN has an average IMD decile of 6.2 (England 5.5, South Ribble 7.0) and a 17.0% Core20 share (England 21.0%, South Ribble 9.9%). Practice Core20 shares vary across a 74.0 pp range: Clayton Brook Surgery records 75.1%, whereas The Village Surgeries Croston&eccleston records 1.1%. Practice estimates sum to 8,813, against 7,717 resident-based Core20 patients. High concentration at Clayton Brook Surgery (2,461 estimated patients) contrasts with volume at Worden Medical Centre (21.9%, 3,098 estimated patients).
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
484
SMI register
0.99% recorded prevalence
272
Learning disability register
0.56% recorded prevalence
27
Care homes, 652 beds
In the PCN catchment
9.5%
Provide unpaid care
South Ribble, Census 2021
The PCN records 484 patients on the severe mental illness register and 272 on the learning disability register (0.6% prevalence vs England 0.6%, South Ribble 0.5%). There are 27 care homes with 652 beds in the PCN catchment, while applying the borough unpaid carer rate (9.5%) provides a ceiling estimate of about 4,700 (4,662) carers. Catchment care home beds and register sizes indicate vulnerable cohorts that may benefit from coordinated.
Severe mental illness: physical health checks
SMI physical health checks record blood pressure at 81.5% (England 83.4%) and BMI at 81.2% (England 82.1%). Smoking cessation support for qualifying conditions was offered to 83.9% of patients (England 94.2%), falling 12.6 pp (England +0.1 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,657
Hypertension register
+6.45%
Register growth, 3 yrs
South Ribble +9.36% · England +5.60%
+0.03pp
BP control, under 80
≤140/90 · −1.66pp aged 80+
+1,519
More patients by 2030
Forecast 10,176 (20.02%)
Hypertension case-finding and control
Leyland PCN records 8,657 patients on its hypertension register (17.7%), above South Ribble (17.6%), the ICB (17.2%) and England (15.2%). However, recent blood pressure recording stands at 87.0%, below South Ribble (89.7%), the ICB (89.0%) and England (90.0%). Treatment to target reaches 65.9%, trailing South Ribble (70.9%), the ICB (70.3%) and England (70.3%), with control at 63.4% for patients aged under 80 (England 67.8%) and 76.1% for those aged 80 and over (England 81.2%). Lower treatment to target than England despite higher recorded prevalence suggests prioritising medication titration and systematic recall for uncontrolled hypertensive patients.
Lipids and statins
For patients with QRISK ≥20%, lipid-lowering therapy is 57.2%, trailing South Ribble (60.0%), the ICB (61.4%) and England (63.6%). Statin coverage for diabetes aged 40+ without CVD is 66.7% (England 73.2%). Fewer at-risk patients receive lipid-lowering therapy than England benchmarks, indicating a gap in primary prevention prescribing.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 84,115 | £1.60 | £1.64 | £1.86 | £134,584 |
| Cardiovascular (all), 2025 | 130,990 | £3.63 | £3.38 | £3.33 | £475,494 |
In 2026, the PCN prescribed 84,115 lipid-regulating drug items at £1.60 per item, below South Ribble (£1.63), the ICB (£1.64) and England (£1.86), which is £21,870 less than at England's unit cost. Lower unit costs reflect formulary choices, though unit cost does not indicate prescribing efficiency or clinical appropriateness.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−5.20%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.52%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.4% (3,447 patients; England 6.6%). Annual reviews fell 5.2% (England +4.4%) to 64.0% (England 65.7%), representing about 1,200 unreviewed patients (1,240). Asthma prescribing in ages 5-19 reached 1,717 per 1,000 (England 1,488). COPD prevalence is 2.0% (996 patients; England 1.9%), but reviews fell 9.4% (England +2.8%) to 72.8% (England 76.4%). Higher youth prescribing with falling reviews could reflect symptom management reliance, which inhaler audits could test.
Cancer register and children's immunisation
Cancer register prevalence is 4.8% (2,334 patients; England 3.8%). In Q1 2025/26 (cohort 136), age-5 MMR dose 1 coverage is 95.6% (England 91.7%), but dose 2 and the 4-in-1 booster both reach 86.8% (England 82.8% and 80.9%), sitting 8.2 pp below the 95.0% target with an 8.8 pp MMR dose difference.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
Across NHS Lancashire and South Cumbria ICB in 2022, 52.4% of cancers with a known stage were diagnosed at stage 1 or 2, trailing England (55.3%) and sitting 22.6 pp below the 75.0% national ambition. Known-stage completeness was 74.6% (8,863 of 11,883 registered cancers), with about 2,010 extra early-stage cases needed annually across the ICB to reach 75%, where early diagnosis fell 1.2 pp from 2013 to 2022. PCN breast screening reaches 76.2% (England 69.9%) and cervical screening is 74.1% (England 66.8%), though Clayton Brook Surgery records 61.7%. Systemic staging shortfalls highlight wider-system delays despite strong PCN screening uptake.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Lancashire Teaching Hospitals NHS Foundation Trust achieved 82.9% on the 28-day faster diagnosis standard, exceeding the 75.0% standard, the ICB (78.4%) and England (79.3%). However, 62-day treatment was 75.0% (10.0 pp below the 85.0% standard; ICB 73.6%, England 71.2%), and 31-day treatment was 89.4% (standard 96.0%; ICB 93.6%, England 92.5%). CT diagnostic lists had 15.0% waiting 6+ weeks (England 9.9%), while MRI 6+ week waits were 2.4% (England 21.4%). Provider treatment delays and CT waiting times could lengthen cancer pathway intervals for referred patients.
| Pathways within standard (%) | Lancashire | Wrightington, Wigan and Leigh | East Lancashire | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 82.90 | 82.80 | 81.50 | 78.39 | 79.32 |
| 31-day treatment (96%) | 89.43 | 89.04 | 98.11 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 75.04 | 76.78 | 73.16 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Lancashire | Wrightington, Wigan and Leigh | East Lancashire | England |
|---|---|---|---|---|
| MRI | 2.41 | 0.49 | 0.43 | 21.40 |
| CT | 14.97 | 7.78 | 0.15 | 9.92 |
| Echocardiography | 13.85 | 24.37 | 0.00 | 28.48 |
| Colonoscopy | 0.00 | 6.10 | 0.95 | 30.83 |
| Gastroscopy | 0.00 | 12.54 | 1.16 | 29.02 |
| All 15 DM01 tests | 26.65 | 14.36 | 3.25 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). For South Ribble residents in June 2026, community health service activity recorded 126,445 total contacts, of which 72,000 involved adults aged 65 and over, representing a 56.9% share. High community contact volume among older residents highlights demand for coordinated post-treatment and community support.
Practice variation and patient experience
Practice-level QOF achievement and phone access show marked variation across member surgeries
In 2025/26, overall QOF achievement ranged from 92.0% at Clayton Brook Surgery to 98.1% at The Village Surgeries Croston&eccleston (England 92.5%). Vaccination and immunisation achievement spanned 46.0 pp, from 37.5% at Clayton Brook Surgery to 83.5% at The Village Surgeries Croston&eccleston (England 55.2%). Achievement points vary widely across member practices.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Worden | 122 | 21.9 | 49.5% | 73.9% | 89.3% |
| Village Surgeries | 114 | 1.1 | 83.6% | 75.1% | 87.6% |
| Sandy Lane Surgery | 103 | 11.6 | 81.3% | 63.5% | 81.3% |
| Central Park | 105 | 10.7 | 79.7% | 78.9% | 81.1% |
| Moss Side | 90 | 27.9 | 55.5% | 83.5% | 75.1% |
| Clayton Brook | 103 | 75.1 | 71.7% | 65.9% | 74.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fifteen of 25 tracked measures trailed national three-year trends between 2023 and 2025
Between 2023 and 2025, 15 of 25 tracked measures trailed England's three-year change. The widest lags include smoking cessation support offered, which fell 12.6 pp (England +0.1 pp), and learning disability prevalence, falling 9.3% (England +5.4%). Routine reviews also dropped: COPD reviews fell 9.4% (England +2.8%) and heart failure reviews fell 2.7% (England +8.7%), although heart failure review completion stands at 82.3% (England 78.5%). Strengths include breast screening coverage from 2023 to 2024 (+12.2% vs England +8.4%) and diabetes statin therapy without cardiovascular disease (+3.9% vs England +2.1%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Smoking support (SMI)
COPD reviews
Heart failure reviews
Asthma reviews
Breast screening (53-70)
Diabetes statin (no CVD)
Diabetes statin (CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | South Ribble | Asset | PCN | South Ribble |
|---|---|---|---|---|---|
| Care homes (catchment) | 27 (652 beds) | n/a | Schools (catchment) | 50 | n/a |
| Children's centres | 4 | 6 | Places of worship | 37 | 60 |
| Libraries | n/a | 3 | Primary schools (LA maintained) | 21 | 32 |
| Primary academies | 4 | 4 | Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma review coverage is 64.0% across 3,447 patients (South Ribble 66.0%, ICB 65.0%, England 65.7%), falling 5.2% from 2023 to 2025 (England +4.4%), leaving about 1,200 (1,240) unreviewed. For discussion: run structured recall using a shared review template, after-school slots, and concurrent inhaler checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Age-five MMR booster recall
In Q1 2025/26 (cohort 136), age-5 MMR dose 1 is 95.6% (England 91.7%) while dose 2 is 86.8% (ICB 87.4%, England 82.8%), an 8.8 pp difference sitting 8.2 pp below the 95.0% target. For discussion: audit age-five cohorts for missing second doses and offer flexible catch-up slots alongside pre-school boosters. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Cardiovascular therapy and BP escalation
Despite 17.7% hypertension prevalence (8,657 patients vs England 15.2%), BP control to target is 65.9% (South Ribble 70.9%, ICB 70.3%, England 70.3%) and QRISK ≥20% lipid therapy is 57.2% (England 63.6%). For discussion: deploy pharmacist-led recall for patients above blood pressure targets or with QRISK ≥20% not on lipid-lowering therapy. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Proactive older adult care planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Dual-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation support recall (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure control audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Age-five MMR booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Cardiovascular therapy and BP escalation (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
